KCM
APGE

Kennedy Capital Management’s Apogee Therapeutics APGE Stock Holding History

Kennedy Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.49M Sell
63,981
-58,688
-48% -$5.29M 0.15% 232
2026
Q1 		$10.3M Sell
122,669
-2,310
-2% -$168K 0.22% 170
2025
Q4 		$9.43M Buy
124,979
+928
+0.7% +$58.5K 0.2% 176
2025
Q3 		$4.93M Buy
124,051
+48,154
+63% +$1.84M 0.11% 298
2025
Q2 		$3.3M Sell
75,897
-2,500
-3% -$95.1K 0.08% 359
2025
Q1 		$2.93M Buy
78,397
+6,090
+8% +$235K 0.07% 371
2024
Q4 		$3.28M Buy
72,307
+31,113
+76% +$1.59M 0.07% 410
2024
Q3 		$2.42M Buy
41,194
+8,755
+27% +$419K 0.05% 477
2024
Q2 		$1.28M Buy
32,439
+29,251
+918% +$1.42M 0.03% 565
2024
Q1 		$212K Buy
+3,188
New +$139K ﹤0.01% 702

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Kennedy Capital Management's APGE Position: Q2 2026 in Review

Kennedy Capital Management reduced its Apogee Therapeutics (APGE) stake by 48% in Q2 2026, selling an estimated $5.29M and leaving 63,981 shares worth $8.49M. The position accounts for 0.15% of the portfolio, ranked #232.

Kennedy Capital Management first reported a position in APGE in Q1 2024 and has held it in 10 quarters since. The position peaked at $10.3M in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Kennedy Capital Management held 63,981 shares of Apogee Therapeutics worth $8.49M as of Q2 2026.
  • Kennedy Capital Management sold 58,688 Apogee Therapeutics shares in Q2 2026, an estimated $5.29M.
  • Apogee Therapeutics made up 0.15% of Kennedy Capital Management's portfolio in Q2 2026, its #232 holding.
  • Kennedy Capital Management first reported a position in Apogee Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Kennedy Capital Management's Apogee Therapeutics position peaked at $10.3M in Q1 2026.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.